Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis

doi:10.3315/jdcr.2010.1050

Contents

Abstract
Keywords

Download PDF pdf

Download XML

162 Views

107 Downloads

Share this article

Research Article | Volume 4 Issue 3 (None, 2010) | Pages 44 - 46

Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis

Uwe Wollina

Under a Creative Commons license

Open Access

DOI : 10.3315/jdcr.2010.1050

PMID : PMC3157817

Received

Nov. 6, 2010

Published

Dec. 19, 2010

Abstract

Background:New targeted therapies have been developed for inflammatory and neoplastic diseases.Main observation:We report on a 73-year-old woman who developed multiple eruptive periungual and subungual pyogenic granulomas. Because of severe rheumatoid arthritis the patient was treated with monoclonal anti-CD20 antibodies. Eruptive granuloma pyogenicum developed after the second antibody application and remained more than 8 weeks after targeted therapy was over. New lesions, however, did not appear.Conclusion:Eruptive granuloma pyogenicum of the nail apparatus is a possible new rare adverse effect of targeted therapies. To the best of our knowledge this is the first case in association with anti-CD20 antibody treatment.

Keywords

Adverse events

Eruptive granuloma pyogenicum

Nails

Rituximab

Rheumatoid arthritis

Recommended Articles

Research Article

A Comparartive Study For The Role Of Color Doppler And Clinical Examination In The Management Of Varicose Vein

Anish Deepak Baxla,

...

Kumar Yogesh